



Seasonal influenza vaccine high dose boosting in solid organ transplant recipients

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over This study is NOT accepting healthy

volunteers

Inclusion Criteria:

- at least 18 years old - history of a solid organ transplant (liver, lung, heart, kidney, pancreas) at least 1 year before starting the study

Exclusion Criteria:

- women who are pregnant - received ATG or carfilzomib in the past 3 months

•received rituximab or basiliximab in the past 3 months - prednisone dose is greater than 20mg/ day - history of a severe allergy to influenza vaccine (e.g., Guillain-Barre syndrome, anaphylaxis, or angioedema) - have received the influenza vaccine for the current season

Conditions & Interventions

Interventions:

Drug: Fluzone High-Dose Quadrivalent- 1 dose of HD, Drug: Fluzone High-Dose Quadrivalent- 2 doses

Conditions:

Infectious Diseases

Keywords:

Clinics and Surgery Center (CSC), influenza, influenza vaccine, Solid organ transplant

More Information

Description: We know that patients who have undergone a solid organ transplant are at higher risk for severe influenza infections and may not develop a robust antibody response to a single dose of the influenza vaccine. The purpose of this study is to better understand the body's response to two doses of the high-dose influenza vaccine compared to one dose during an influenza season.

Study Contact: Flue Vaccine Study - fluvaccinestudy@umn.edu

Principal Investigator: Lauren Fontana

IRB

Number: STUDY00017687

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.